Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Oct 16, 2023 1:08pm

182 Views

Post# 35685648

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

@consultant99: Been wondering the same. I think it might be the hangover from Photofrin and it's side effects that may be hampering the acceptance of PDTs as a mainstream option. Hopefully, the message about safety will get through eventually. Don't know about convertible debentures as an option. They don't have anything other than patents as an asset right now. Once those are validated via a BTD, it might allow them to consider it? Thanks for your thoughts.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario